Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 6:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 41 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Fuchs Dystrophy Clear all
Completed Phase 2 Interventional

A Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD)

NCT05376176
View directory record Official record
Conditions
Fuchs Endothelial Corneal Dystrophy
Interventions
STN1010904 ophthalmic suspension 0.03% BID, STN1010904 ophthalmic suspension 0.1% BID, Placebo (Vehicle) BID
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
30 Years to 75 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
11
States / cities
Los Angeles, California • Indianapolis, Indiana • Baltimore, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Jul 21, 2026, 6:22 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Safety and Efficacy of K-321 Eye Drops After Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)

NCT05795699
View directory record Official record
Conditions
Fuchs Endothelial Corneal Dystrophy
Interventions
Ripasudil, Placebo
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
26
States / cities
Los Angeles, California • Palo Alto, California • Sacramento, California + 20 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Jul 21, 2026, 6:22 PM EDT
Completed Phase 4 Interventional Results available

Comparison of Corticosteroid Dosing Regimens After Endothelial Keratoplasty

NCT01853696
View directory record Official record
Conditions
Fuchs' Dystrophy, Corneal Edema
Interventions
loteprednol etabonate, prednisolone acetate 1%
Drug
Lead sponsor
Cornea Research Foundation of America
Other
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 14, 2015 · Synced Jul 21, 2026, 6:22 PM EDT
Terminated No phase listed Observational

Using the Optovue OCT to Select IOL Power

NCT01361282
View directory record Official record
Conditions
Fuchs' Endothelial Dystrophy, Cataract
Interventions
Not listed
Lead sponsor
Legacy Health System
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 12, 2017 · Synced Jul 21, 2026, 6:22 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for the Treatment of Fuchs' Corneal Endothelial Dystrophy (FCED)

NCT02653391
View directory record Official record
Conditions
Fuchs' Corneal Endothelial Dystrophy (FCED)
Interventions
Part A Elamipretide 1.0% Ophthalmic Solution, Part B Elamipretide 3.0% Ophthalmic Solution, Part A Placebo, Part B Placebo
Drug
Lead sponsor
Stealth BioTherapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Edgewood, Kentucky • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Jul 21, 2026, 6:22 PM EDT
Completed Phase 2 Interventional Results available

Study to Investigate the Safety and Efficacy of K-321 in Patients With Fuchs Endothelial Corneal Dystrophy (FECD) Following Descemetorhexis

NCT04250207
View directory record Official record
Conditions
Fuchs' Endothelial Corneal Dystrophy
Interventions
K-321 Solution, Placebo Solution
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
19
States / cities
Los Angeles, California • Palo Alto, California • Sacramento, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Jul 21, 2026, 6:22 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase 1/ Phase 2 Study of TTHX1114(NM141)

NCT04520321
View directory record Official record
Conditions
Corneal Endothelial Dystrophy, Fuchs Endothelial Corneal Dystrophy, Pseudophakic Bullous Keratopathy, Endothelial Dysfunction
Interventions
TTHX1114(NM141), Vehicle (placebo)
Drug · Other
Lead sponsor
Trefoil Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
8
States / cities
Petaluma, California • Jacksonville, Florida • Hoffman Estates, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2023 · Synced Jul 21, 2026, 6:22 PM EDT
Completed Not applicable Interventional Results available

Study of Eye Bank Pre-cut Donor Grafts for Endothelial Keratoplasty

NCT00624221
View directory record Official record
Conditions
Fuchs Endothelial Dystrophy, Corneal Edema
Interventions
Descemet's stripping endothelial keratoplasty
Procedure
Lead sponsor
Cornea Research Foundation of America
Other
Eligibility
21 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 26, 2016 · Synced Jul 21, 2026, 6:22 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study Evaluating the Safety and Efficacy of Netarsudil Ophthalmic Solution in Patients With Corneal Edema Due to Fuchs Corneal Dystrophy

NCT04498169
View directory record Official record
Conditions
Corneal Edema
Interventions
Netarsudil Ophthalmic
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
12
States / cities
Garden Grove, California • Laguna Hills, California • Edgewood, Kentucky + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2022 · Synced Jul 21, 2026, 6:22 PM EDT
Completed Phase 3 Interventional

A Study to Investigate the Safety and Efficacy of K-321 Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)

NCT05826353
View directory record Official record
Conditions
Fuchs Endothelial Corneal Dystrophy
Interventions
Ripasudil, Placebo
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
21
States / cities
Los Angeles, California • Palo Alto, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Jul 21, 2026, 6:22 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

A Study to Test the Diagnostic Potential of Brillouin Microscopy for Corneal Ectasia

NCT02118922
View directory record Official record
Conditions
Keratoconus, Ectasia, Crosslinking, Fuchs' Endothelial Dystrophy
Interventions
Brillouin imaging
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
20 Years to 75 Years
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Jul 21, 2026, 6:22 PM EDT
Completed Not applicable Interventional Results available

Impact of Donor Diabetes on DMEK Success and Endothelial Cell Loss

NCT05134480
View directory record Official record
Conditions
Corneal Endothelial Decompensation, Fuchs' Endothelial Dystrophy
Interventions
Descemet membrane endothelial keratoplasty
Procedure
Lead sponsor
Case Western Reserve University
Other
Eligibility
30 Years to 90 Years
Enrollment
1,097 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Indianapolis, Indiana • Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Jul 21, 2026, 6:22 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Rhopressa for Corneal Edema Associated With Fuchs Dystrophy

NCT04051463
View directory record Official record
Conditions
Fuchs Endothelial Dystrophy
Interventions
Netarsudil Ophthalmic Solution, Placebo
Drug
Lead sponsor
Price Vision Group
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 18, 2021 · Synced Jul 21, 2026, 6:22 PM EDT
Completed Phase 2 Interventional Results available

Comparison of Two Steroid Regimens to Prevent Transplant Rejection After Corneal Transplant (DMEK)

NCT01448213
View directory record Official record
Conditions
Fuchs' Dystrophy, Bullous Keratopathy
Interventions
Prednisolone acetate, Fluorometholone
Drug
Lead sponsor
Price Vision Group
Industry
Eligibility
18 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 2, 2014 · Synced Jul 21, 2026, 6:22 PM EDT
Terminated Not applicable Interventional

OCT-guided DSAEK Graft Shaping and Smoothing

NCT01586234
View directory record Official record
Conditions
Fuchs' Endothelial Dystrophy
Interventions
DSAEK with graft shaping and smoothing, Standard DSAEK
Procedure
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 16, 2018 · Synced Jul 21, 2026, 6:22 PM EDT
Completed Phase 3 Interventional Results available

Trial of Netarsudil for Prevention of Corticosteroid-induced Intraocular Pressure Elevation

NCT03248037
View directory record Official record
Conditions
Fuchs' Endothelial Dystrophy, Bullous Keratopathy
Interventions
Netarsudil, Placebo
Drug
Lead sponsor
Cornea Research Foundation of America
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Jul 21, 2026, 6:22 PM EDT
Completed No phase listed Observational

Association Between Fuchs' Endothelial Corneal Dystrophy Severity and Estrogen Exposure

NCT04564378
View directory record Official record
Conditions
Fuchs Dystrophy
Interventions
This is an observational study. There is no therapeutic intervention.
Other
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
55 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 30, 2024 · Synced Jul 21, 2026, 6:22 PM EDT
Recruiting Phase 2 Interventional

Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy

NCT04440280
View directory record Official record
Conditions
Fuchs Endothelial Corneal Dystrophy
Interventions
N-acetyl cysteine (NAC) 10% solution, N-acetyl cysteine (NAC) 20% solution, Visine Dry Eye Relief eye drops
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
21 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 28, 2025 · Synced Jul 21, 2026, 6:22 PM EDT
Recruiting Phase 3 Interventional

Descemet Endothelial Thickness Comparison Trial II

NCT05275972
View directory record Official record
Conditions
Fuchs, Fuchs Dystrophy, Fuchs' Endothelial Dystrophy
Interventions
Ripasudil, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
8
States / cities
Palo Alto, California • Sacramento, California • Palm Beach Gardens, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Jul 21, 2026, 6:22 PM EDT
Completed Not applicable Interventional

A Comparison Between Full Thickness and Partial Thickness Corneal Transplantation for Corneal Edema

NCT00346138
View directory record Official record
Conditions
Fuchs Dystrophy, Corneal Edema
Interventions
Corneal transplantation
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 14, 2010 · Synced Jul 21, 2026, 6:22 PM EDT
Completed Not applicable Interventional

Study of Endothelial Keratoplasty Outcomes

NCT00800111
View directory record Official record
Conditions
Fuchs' Endothelial Corneal Dystrophy, Bullous Keratopathy, Iridocorneal Endothelial Syndrome, Posterior Polymorphous Dystrophy
Interventions
endothelial keratoplasty
Procedure
Lead sponsor
Cornea Research Foundation of America
Other
Eligibility
18 Years and older
Enrollment
2,593 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Jul 21, 2026, 6:22 PM EDT
Recruiting Phase 2 Interventional

DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy

NCT07024693
View directory record Official record
Conditions
Fuchs Endothelial Corneal Dystrophy, Fuchs
Interventions
DT-168
Drug
Lead sponsor
Design Therapeutics, Inc.
Industry
Eligibility
30 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Indianapolis, Indiana • Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 28, 2025 · Synced Jul 21, 2026, 6:22 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Early Experience With Descemet's Stripping Automated Endothelial Keratoplasty

NCT00744796
View directory record Official record
Conditions
Corneal Edema Secondary to Corneal Endothelial Dystrophy
Interventions
DSAEK, Anterior Segment Optical Coherence Topography (OCT), Best Spectacle Corrected Visual Acuity (BSCVA)
Procedure · Diagnostic Test
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Jul 21, 2026, 6:22 PM EDT
Withdrawn Phase 1Phase 2 Interventional Accepts healthy volunteers

Assessment of Corneal Endothelial Function Following Hypoxic Stress

NCT04175938
View directory record Official record
Conditions
Fuchs' Endothelial Corneal Dystrophy
Interventions
Wearing of contact lens
Device
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Jul 21, 2026, 6:22 PM EDT